An introduction from
our management

- Chairman's Statement

- Letter from the CEO

o1
Chiesi at a Glance

02
Positive Impacts
and Challenges

- Products and Patients
~ Processes

- Global Value Chain

- Corporate Citizenship

03

Chiesi’s contribution
to the UN Sustainable
Development Goals

04
Annexes
- Impact Report
- Data, Methodology
and GRI Content Index

This analysis led to the identification of the following material topics:

Citizenship

Products
Te Mera

 

SAN
TOPIC

Ethics and
compliance

Transparency

Product quality
and reliability

Research and
development

Patients health
and safety

Access to
healthcare

Sustainable
products

GENERAL DEFINITION

Compliance with national laws and regula-
tions in place in the countries in which the
Group is operating. The Group's commit-
ment to promote good relationships and fair
practices with all of its business partners; in
particular, enforcing principles like freedom
of contract, fair dealing, written agreemen-
ts and confidentiality. Group's commitment
to employee training concerning the ethical
code of conduct and adoption of whist-
leblowers policy and procedures.

Transparency about tax, economic contri-
butions, clinical trials and reporting of the
company’s impact, both positive impact and
areas of improvement, including non-finan-
cial topics.

Activities and procedures aimed at offering
high-quality products and services, through
the implementation of defined actions to
guarantee the quality and safety of the com-
pany’s products and their compliance with
laws and regulations.

Research and Development activities aimed
at discovering new therapeutic solutions for
significant unmet medical needs. The topic
also considers the use of innovative tech-
nologies, patents, intellectual property and
avant-garde know-how.

Activities and procedures aimed at offering
high quality products and services to ensure
the protection of patients’ health and safety.
Including patient engagement and involve-
ment activities in our business.

Contributing to increased access to healthca-
re through our: products in specific therapeu-
tic areas, including rare diseases; meeting
patient needs through engagement activities;
and working alongside healthcare authorities
to increase disease awareness and promote
training for healthcare professionals, inclu-
ding those in low- and middle-income coun-
tries.

Assessment and management of the envi-
ronmental impact of our products by taking
into consideration the entire life cycle throu-
ghout the value chain.

18

Chiesi at a glance
